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SHOC2 scaffold protein has been mainly related to oncogenic ERK signaling through the RAS‑
SHOC2‑PP1 phosphatase complex. In leukemic cells however, SHOC2 upregulation has been 
previously related to an increased 5‑year event‑free survival of pediatric pre‑B acute lymphoid 
leukemia, suggesting that SHOC2 could be a potential prognostic marker. To address such paradoxical 
function, our study investigated how SHOC2 impact leukemic cells drug response. Our transcriptome 
analysis has shown that SHOC2 can modulate the DNA‑damage mediated by p53. Notably, upon 
genetic inhibition of SHOC2 we observed a significant impairment of p53 expression, which in turn, 
leads to the blockage of key apoptotic molecules. To confirm the specificity of DNA‑damage related 
modulation, several anti‑leukemic drugs has been tested and we did confirm that the proposed 
mechanism impairs cell death upon daunorubicin‑induced DNA damage of human lymphoid cells. In 
conclusion, our study uncovers new insights into SHOC2 function and reveals that this scaffold protein 
may be essential to activate a novel mechanism of p53‑induced cell death in pre‑B lymphoid cells.
SHOC2 is a scaffold protein that acts as part of the RAS-SHOC2-PP1 phosphatase complex to facilitate interac-
tions of core signaling partners of the ERK  pathway1. Since ERK1/2 signaling is involved in regulating several 
critical cellular processes, numerous studies have explored the biological significance of SHOC2 in the ERK 
pathway. For instance, gain-of-function germline mutations have been extensively studied in RASopathies, such 
as Noonan syndrome, and more recently gain-of-function somatic mutations of SHOC2 have been related to 
oncogenic ERK signaling in solid tumors such as lung and pancreatic  cancer2–4. SHOC2 has also been shown 
to be involved in autophagy-mediated cell death through RAS-ERK-mTOR axis crosstalk by controlling key 
autophagy molecules such as RICTOR and  RAPTOR4.
However, at present, a specific role for SHOC2 scaffold function in tumorigenesis and drug response has 
not been described. In a previous study, our group has shown that SHOC2 upregulation significantly increased 
the 5-year event-free survival of pediatric patients with pre-B acute lymphoid leukemia (ALL). This finding 
was observed both in univariate and multivariate analysis, suggesting that SHOC2 scaffold protein could be 
a potential prognostic marker for a favorable outcome in this  cohort5. Since increased SHOC2 could provide 
oncogenic activation through ERK/MAPK signaling, this finding was unexpected and prompted us to investigate 
how SHOC2 absence would impact lymphoid leukemia cells. Here we show that genetic inhibition of SHOC2 
promotes cell proliferation and chemoresistance when treating human lymphoid cell lines with the anthracycline 
daunorubicin (DNR). Furthermore, SHOC2 inhibition reduced p53 expression, leading to the blockage of key 
apoptotic molecules and thus, impairing cell death upon DNA damage stress. Our study uncovers new insights 
into SHOC2 function and reveals that SHOC2 may be essential to activate a novel mechanism of p53-induced 
cell death in pre-B lymphoid cells.
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Results and discussion
First, to gain insights into the underlying mechanisms of SHOC2 in pre-B ALL we examined how SHOC2 
knockdown affects the mRNA and miR transcriptome profile of human B lymphoid leukemia Reh (ATCC CRL-
8286) (Supplementary microarray data). To that aim a set of down-regulated and up-regulated mRNA (Fold 
change > 5.0) and miR transcripts were analyzed by functional analysis of biological process and for pathway 
enrichment. Of note, the GO enrichment analysis pointed to “intrinsic apoptotic signaling pathway in response 
to DNA damage by p53 class-mediator” as the most important biological process (Fig. 1a; Additional GO path-
ways are described in Supplementary Fig. 1a). Similarly, miR-System Pathway Enrichment predicted targets to 
be direct p53-effectors (Fig. 1b). Our mRNA transcriptome finding was validated in two independent public 
domain microarray datasets of pediatric pre-B ALL (GSE7440 and GSE11877), in which in silico analysis of 
the same gene-set showed a similar pattern for SHOC2-related gene expression (Fig. 1c,d). Additionally, we 
observed that SHOC2 upregulation was significantly associated with complete clinical remission in the GSE7440 
ALL datasets when compared to relapsed patients (Fig. 1e) suggesting that its expression was related to early 
response and a favorable outcome. Together, these data corroborate our previous  findings5 on SHOC2 potential 
as a prognostic marker and strongly suggest that SHOC2 may play a role in DNA damage-induced cell death 
mediated by p53-axis.
In ALL treatment protocols several cytotoxic agents are used including DNR, which has been widely used 
in remission induction  phase10. Proposed mechanisms for anthracycline action include the generation of toxic 
lesions, DNA damage, and double-strand breaks, leading to apoptosis-induced cell death mediated by  p5311. 
Since our analysis of the downstream effects of SHOC2 inhibition indicated that this gene is involved in p53 
mediated cell death in response to DNA damage we examined the role of SHOC2 inhibition after DNR treat-
ment in 4-day viability assays in two pre-B acute lymphoid leukemia cell lines: Nalm-6 and Reh. DNR treatment 
showed that knockdown of SHOC2 in the two pre-B leukemic cell lines was associated with resistance to DNR-
induced damage effects exhibiting a marked increase in the drug  IC50 values  (IC50 in Reh cells increased from 
20.98 ± 10.94 to 84.47 ± 19.03 and in Nalm-6 cells from 123.24 ± 13.81 to 476.11 ± 25.70; p < 0.05 and p < 0.001, 
respectively) (Fig. 2a-b). These results suggest that SHOC2 is important for DNR efficacy. These findings are 
Figure 1.  (a) Reh cells transcriptome profile. Enriched Gene ontology (GO) biological processes of the 
differentially expressed mRNA transcripts (Fold change > 5.0) between control (SCR) and SHOC2 knockdown 
was performed by DAVID Functional Annotation Bioinformatics Microarray Analysis tool. The most important 
biological process—GO:0042771 “intrinsic apoptotic signaling pathway in response do DNA damage by p53 class-
mediator” suggest p53-related pathways, followed by GO:0051781 “positive regulation of cell division”. Among 
the top regulated genes are TOPORS, VEGFA, ARAP2 and TAF1 all p53 related genes as previously  reported6–9. 
(b) A set of most differentially expressed miR transcripts upon SHOC2 knockdown were subjected to functional 
enrichment using miR-System Pathway Enrichment tool. The major class of miR transcripts predicted targets 
which are direct p53-effectors (total genes of the Term: 137; https ://publi c.ndexb io.org/#/netwo rk/67c3b 
75d-6191-11e5-8ac5-06603 eb7f3 03). (c,d) SHOC2 expression analysis was performed using two independent 
public domain microarray data-set of pediatric pre-B ALL (GSE7440 and GSE11877) which showed similar 
patterns for SHOC2-correlated gene-sets. (e) SHOC2 expression profile analysis from high-risk ALL patients 
regarding early response and outcome (GSE7440). SHOC2 upregulation was observed in patients who presented 
a complete clinical remission (CCR) compared to patients who relapsed (RELAPSE) (p < 0.001).
3Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15193  | https://doi.org/10.1038/s41598-020-72124-1
www.nature.com/scientificreports/
supported by previously published data that have identified SHOC2 among a set of differentially expressed 
genes related to DNR-sensitive B-lineage  ALL12. To determine whether SHOC2-mediated response was specific 
to DNR, we tested the major anti-leukemic chemotherapy agents: Methylprednisolone, L-asparaginase and 
Vincristine in Reh pre-B cells (Sigma-Aldrich, Steinheim, Germany). In keeping with the idea that response to 
SHOC2 knockdown was specific for DNR, there was no apparent modification of the intrinsic response of the 
cells (Supplementary Fig. 2a-d).
To address daunorubicin-induced cell death, SHOC2-inhibited Nalm-6 and Reh cells were treated with DNR 
and apoptosis was measured after 72 h. DNR-induced cell death was SHOC2-dependent in both pre-B cell lines 
in comparison to control (shSCR) cells (Fig. 2c,d). Interestingly, in T-ALL Jurkat cells, which is p53 deficient, 
neither apoptosis nor cell proliferation modulation was apparent (Supplementary Fig. 3a–c). These data confirm 
that SHOC2 can mediate DNR effects in pre-B ALL cells and are in consonance with our transcriptome data, 
suggesting that SHOC2 could activate the p53 pathway. Next, we performed immunoblot analysis on pre-B 
Nalm-6 cells, which harbor wild type p53, to evaluate if SHOC2 inhibition has any downstream effect and, as 
expected, ERK1/2 phosphorylation was inhibited (Fig. 3a).
We next sought to investigate the modulation of the p53-mediated cell death cascade by SHOC2 upon DNR 
treatment. We found that genetic inhibition of SHOC2 combined with DNR treatment for 24 h in Nalm-6 cells 
significantly reduced p53 expression and impaired Serine 46 phosphorylation (Fig. 3b). This post-translation 
modification of p53 is known to activate damage-induced  apoptosis13. Furthermore, we analyzed whether SHOC2 
is involved in the DNA damage-mediated regulation of p21, the main target of p53  activation14. In agreement with 
previous reports investigating DNA damage  responses15, DNA-damage induced by DNA led to the upregulation 
of p21 levels in wild type Nalm6. However, daunorubicin-induced p21 accumulation was significantly abolished 
in SHOC2 knockdown cells (Fig. 3b). Upon DNR treatment, SHOC2 knockdown impaired crucial effectors of the 
intrinsic apoptotic cascade such as p38 activation and reduced BAX/BCL-2 ratio (Fig. 3b right and left panel). In 
RAS-mutant tumors, however, SHOC2 deletion has been implicated in sustained ERK pathway suppression and 
consequently promotion of BIM-dependent  apoptosis16 suggesting that SHOC2 mechanistic role in cell death 
could act differently in specific tumorigenic contexts. Our findings are the first to demonstrate a relationship 
between SHOC2 and p53-mediated cell death in leukemia response.
Previous studies have demonstrated that the SHOC2 scaffold complex interacts with the E3 ubiquitin-ligase 
HUWE1, which modulates ubiquitination of SHOC2 and RAF-1 utilizing a negative feedback loop that fine-tunes 
ERK1/2  activation17. HUWE1 has been reported to mediate proteasomal degradation of MYC, N-MYC, p53 
Figure 2.  (a,b) Cell viability of Nalm-6 and Reh cells stable transduced with shRNA for SHOC2 or SCR 
control were evaluated in a 4-day MTT assay after treatment with increasing concentrations of Daunorubicin 
(10ηM, 25ηM, 50ηM, 100ηM and 150ηM). Results are expressed as mean absorbance [A475 nm–A650 nm] 
with standard deviation (S.D.) from three independent experiments. Representative viability curves after 
72 h of Daunorubicin exposure show how SHOC2 absence has greatly increased daunorubicin resistance 
(*p < 0.05). (c,d) SHOC2 inhibition cleared impaired apoptosis-induced cell death in both Reh and Nalm-6 
cells (***p < 0.001) after Daunorubicin treatment for 72 h (respective  IC50 values). The bar-graphs represent 
mean with S.D. from three independent experiments. Statistically significant analyses are indicated by asterisks: 
*p < 0.05, **p < 0.01.
4Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:15193  | https://doi.org/10.1038/s41598-020-72124-1
www.nature.com/scientificreports/
and other  proteins18. Since HUWE1 interacts with both SHOC2 and p53, we investigated whether p53-HUWE1 
interaction could be modified by SHOC2. To test this hypothesis, Nalm-6 leukemic cells were transduced with 
shRNA lentiviral constructs targeting HUWE1 and SCR controls to evaluate SHOC2 and p53 protein expression. 
As observed in Fig. 3c, HUWE1 knockdown greatly increased SHOC2 expression, leading to accumulation of 
p53 and p21. Collectively, our findings suggest that SHOC2 plays a role in p53-HUWE1 interactions related to 
proteasomal degradation.
We then analyzed HUWE1 after DNR treatment and there was no difference in HUWE1 expression upon 
DNR-induced damage in SHOC2 knockdown cells compared to control (Fig. 3c). This result was unanticipated 
as we expected that without SHOC2 mediated p53 inactivation there would be HUWE1 upregulation. However, 
this finding does agree with previous studies that have shown that in response to genotoxic stress HUWE1 can 
be downregulated by self-ubiquitination and subsequent proteasomal degradation in an attempt to stabilizes 
 p5319. Here we confirm that upon DNR treatment, p53 modulation through SHOC2 is a HUWE1-independent 
mechanism that points to alternative pathways used by SHOC2 to regulate p53 activation after DNA damage. 
Other mechanisms cannot be ruled out as well, considering the complexity of DNA-damage cell response.
Collectively, our results suggest that the scaffold protein SHOC2 is essential for p53 stabilization and cell death 
control upon daunorubicin-induced DNA damage. This report provides new and relevant insights regarding 
SHOC2 function in DNA damage response and its potential clinical value as a prognostic marker for patients 
with acute lymphoblastic leukemia undergoing daunorubicin treatment.
Methods
Cell culture and knockdown construction. The commercial human Leukemic cell lines Nalm-6 
(DSMZ ACC128), Reh (ATCC CRL-8286) and Jurkat (ATCC TIB-152) were cultured in RPMI 1640 medium 
(Corning, Manassas, VA, USA) supplemented with 10% fetal bovine serum (Gibco BRL, Carlsbad, CA, USA), 
penicillin (100 U/mL) and streptomycin (100 μg/mL) in a humidified atmosphere with 5%CO2 at 37 °C, as rec-
ommended by ATCC. Cell line authentication was performed by Short Tandem Repeats (STR) DNA Profiling 
Analysis and all cell cultures haven been periodically tested to avoid mycoplasma contamination.
All cell lines were stably transduced with lentivirus particles containing short hairpin (sh) RNA constructs 
with selectable markers (GFP and/or puromycin) for SHOC2 gene or scramble shRNA—(shSCR) (Sigma-
Aldrich—Mission shRNA—SHCLNV-NM_007373 and SHC002V). For HUWE1 knockdown cells were trans-
fected with plasmids for lentiviral package (CMV Δ8.91 and VSV-G) and pRRL-SFFV-GFPmiRE plasmid carry-
ing either a scrambled sequence or a shHUWE1 sequence for lentiviral package. Short hairpins sequences were 
Figure 3.  (a) Representative immunoblot of SHOC2 knockdown (obtained from two independent shRNA) 
significantly impaired ERK1/2 phosphorylation. (b) Combined genetic inhibition of SHOC2 with Daunorubicin 
treatment for 24 h (40ηM) in Nalm-6 cells. Immunoblots reveal reduced p53 expression, impaired Serine 46 
phosphorylation and consequently reduced p21 expression upon Daunorubicin-induced damage. Important 
apoptotic effectors were also affected as observed for p38 phosphorylation inhibition and reduced BAX/BCL-2 
ratio (representative bar-graph in the left panel). (c) HUWE1 knockdown in Nalm-6 cells greatly increased 
SHOC2, p53 and p21 expression, confirming SHOC2-p53 interaction. As observed in immunoblot panel in 
(b) after Daunorubicin-induced damage, in SHOC2 absence decreased p53 phosphorylation and also reduced 
HUWE1 expression.
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the following: #1, 5′-TTA ATG TTC GTA AAG AAG CTGC-3′; #2, 5′-TTC CTC TGT ACC AAC AAC CTGC-3′; and 
#3, 5′- TTA AAG TCT GTA CTG CTG CTGC-3′ as previously  described20. All cell lines were transduced with lenti-
virus particles in RPMI 1640 medium (Corning, USA) supplemented with 10% fetal bovine serum, penicillin (100 
U/mL), streptomycin (100 lg/mL) and 4 µg/ml Polybrene (Sigma-Aldrich). The culture medium was removed 
48 h post-transduction and stable cells were selected either per cell sorting or puromycin (#9620, Sigma-Aldrich) 
selection. SHOC2 and HUWE1 knockdown was confirmed by immunoblotting (IB).
mRNA and miR transcriptome analysis. mRNA and miR transcriptome analysis were performed as 
previously  described21. Briefly, Reh cells (1 × 105) transduced either with shRNA for SHOC2 or SCR were used to 
RNA extraction. Total RNA was extracted using the RNeasy mini kit (Qiagen, Courtaboeuf, France) according 
to manufacture instructions. RNA quantification was performed in a NanoDrop Spectrophotometer (Thermo-
scientific, Wilmington, Delaware, USA) and RNA integrity (RIN) was analyzed on the Agilent 2100 BioAnalyzer 
(Santa Clara, California, USA). High quality RNA (RIN > 8.0) was amplified and labeled using the Quick Amp 
Labeling (one color) Kit (Agilent Technologies, Santa Clara, California, USA). The hybridization on microarrays 
was performed using 4 × 44K Agilent Whole Human Genome microarray slides, version 1 (Agilent AMADID 
014850, Santa Clara, California, USA). Data were treated with GeneSpring 11.5 software (Agilent Technolo-
gies) and the method “Significance Analysis of Microarrays paired with permutations (100)” was applied to the 
identification of differentially expressed genes. A lower limit of 5.0-fold change (FC) and a maximum of 1% false 
discovery rate have been assigned to obtain more accurate and significant results.
MicroRNA library was obtained from total RNA (100ηg) and the expression profile was performed using the 
Agilent “Human micro-RNA Microarray Kit (v3)” (G4470C, Agilent Technologies, Santa Clara, CA, USA) as 
previously  reported21. Spot images were processed with Feature Extraction Software v10.7.3.1 (Agilent Technolo-
gies, Santa Clara, CA, USA). Statistical analysis of microarray data regarding differential expression of miRNA 
were performed using the AgiMicroRna AFE package (Agilent Feature Extraction) from the Bioconductor library. 
For miRNA microarray analysis, signal intensity, background signal, internal control blade and spike-in controls 
were used. To determine the differential expression and the false discovery rate (FDR) an empirical Bayesian 
approach was used to control the false-positive rate. Normalization was performed by the 75% quartile method.
Datasets processing and analysis. Two independent data-set samples were obtained from GSE7440 and 
GSE11877 and analyzed thought R2 Genomic Analysis and Visualization platform (https ://r2.amc.nl). We used 
the median values as a cut-off parameter to distinguish patients with high expression or low expression. Gene 
correlation analysis has been performed using Pearson’s correlation test. Additionally, we performed expression 
analysis to compare patients who had complete clinical remission (CCR) with patients who experienced relapse 
(REL) using Mann–Whitney non-parametric test.
Drugs and functional assays. Daunorubicin (DNR #30450), Methylprednisolone (MPRED #BP248), 
L-Asparaginase (L-ASP #A4887) and Vincristine (VCR #V8388) were purchased from Sigma Chemical CO 
(Sigma-Aldrich, Steinhem, Germany). All drugs were dissolved in saline for stock solution preparation and were 
kept at − 20 °C. Drugs were dissolved in culture medium immediately before the experiments. For cell viability 
assays cells were seeded (1 × 104 cells/well) in 96-well plates in complete RPMI 1640 medium, in a final volume of 
200 μL. A 4-day MTT Assay (according to manufacturer’s instructions) was performed for each drug.  IC50 values 
were calculated using the CalcuSyn Software (Biosoft, Cambridge, UK).
To address apoptosis, a total amount of 5 × 105 cells were plated in a six-well plate and treated independently 
with DNR, MPRED and VCR for 72 h with the respective  IC50 values for each cell line. Isolated cells from culture 
were washed and labeled with FITC Annexin-V (BD Biosciences, #556419) and propidium iodide, according to 
manufacturer’s instructions. Fluorescence was accessed in the BD FACSCalibur (BD Biosciences) and analysis 
was performed in FlowJo Software (FlowJo, LLC, 2013–2017).
Immunoblotting. Cells were lysed in RIPA buffer on ice for 15 min. Lysates were probed with the primary 
antibodies: anti-SHOC2, anti-phospho-p44/42 MAPK (Erk1/2), anti-p44/42 MAPK (Erk1/2), anti-phospho-38, 
anti-p38, anti-phospho-p53 (Ser46), anti-p21 (#53600, #9101, #9102, #9211, #9212, #2521 and #2947 respec-
tively, Cell Signaling Technology, Inc.); p53 (DO-1), Bax (B-9), Bcl-2 (C-2), Vinculin (N-19), β-actin (C4) and 
α-tubulin (B-7) (sc-126, sc-7480, sc-7382, sc-7649, sc-47778 and sc-5286, respectively; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, EUA); Anti-HUWE1 (Lasu1/Ureb1, A300-486A, Bethyl Laboratories, Inc). Horseradish 
peroxidase (HRP)-linked secondary antibodies were used as appropriated (sc-516102; sc-2357; Santa Cruz Bio-
technology). Immunoblots were quantified by densitometry using Image J 1.52a.
Statistical analysis. Data were presented as the mean ± SD from triplicates of three independent experi-
ments. Statistical analysis was carried out using one-way or two-way analysis of variance, followed by Bonfer-
roni’s test, as appropriate, and Student’s t-test. Alpha value was set at 0.05 and significant p value denoted by 
* (*p < 0.05, **p < 0.01 and ***p < 0.001). Data analysis was carried out using the SPSS 17.0 statistical software 
package (SPSS Inc., Chicago, Illinois, USA).
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